Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines Aug 28, 2026 Life Science
Beyond Eli Lilly and Novo Nordisk: Overlooked Opportunities in the GLP-1 Race Aug 25, 2026 Life Science
Moderna Surges Nearly 60%, But Clinical Win Has Yet to Reverse Financial Slide Aug 19, 2026 Life Science
Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027? Aug 7, 2026 Life Science
Down 46%, Yet Wall Street Predicts a 161% Surge: Would You Bet on This Weight-Loss Drug Stock? Aug 6, 2026 Life Science
Vertex Tops Q2 Estimates, But Investors Shift Focus to Crinetics Deal Integration Aug 4, 2026 Life Science
